CP-465022 (maleate) hrin-β Smiles: COC1C=CC=C2OC[C@H]3CN(CCCCN4C(=O)NC5=C(SC6=NC=C(N=C56)C5C=CC=CC=5)C4=O)C[C@H]3C=12

Smiles: COC1C=CC=C2OC[C@H]3CN(CCCCN4C(=O)NC5=C(SC6=NC=C(N=C56)C5C=CC=CC=5)C4=O)C[C@H]3C=12

Erythromycin dihyrate acts by binding to bacterial 50S ribosomal subunits and inhibits RNA-dependent protein synthesis by blockage of transpeptidation and/or translocation reactions

9 μM for epidermal growth factor receptors (EGFR) and 2

CDK9 inhibitor is a small-molecule selective inhibitor of CDK9 (cyclin dependent kinase 9) with IC50 value of 39 nM

CP-465022 (maleate) hrin-β Smiles: COC1C=CC=C2OC[C@H]3CN(CCCCN4C(=O)NC5=C(SC6=NC=C(N=C56)C5C=CC=CC=5)C4=O)C[C@H]3C=12IC50: 25 nM for AMPA receptor mediated currents in rat cortical neurons CP 465022 is an AMPA antagonist. The inhibition of alpha amino 3 hydroxy 5 methyl 4 isoxazolepropionic acid (AMPA) receptor has been hypothesized to lead to neuroprotective efficacy after cerebral ischemia on the basis of the activity in ischemia models of a variety of compounds with varying selectivity for AMPA over other glutamate receptor subtypes. In vitro: CP 465022 inhibited